- Home
- TERN vs MNMD Comparison
TERN vs MNMD Comparison
Compare TERN & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- MNMD
- Stock Information
- Founded
- TERN 2017
- MNMD 2019
- Country
- TERN United States
- MNMD United States
- Employees
- TERN N/A
- MNMD N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- MNMD Pharmaceuticals and Biotechnology
- Sector
- TERN Health Care
- MNMD Health Care
- Exchange
- TERN Nasdaq
- MNMD Nasdaq
- Market Cap
- TERN 495.2M
- MNMD 509.2M
- IPO Year
- TERN 2021
- MNMD N/A
- Fundamental
- Price
- TERN $7.06
- MNMD $9.60
- Analyst Decision
- TERN Buy
- MNMD Strong Buy
- Analyst Count
- TERN 5
- MNMD 7
- Target Price
- TERN $15.63
- MNMD $24.71
- AVG Volume (30 Days)
- TERN 1.0M
- MNMD 1.3M
- Earning Date
- TERN 08-05-2025
- MNMD 07-31-2025
- Dividend Yield
- TERN N/A
- MNMD N/A
- EPS Growth
- TERN N/A
- MNMD N/A
- EPS
- TERN N/A
- MNMD N/A
- Revenue
- TERN N/A
- MNMD N/A
- Revenue This Year
- TERN N/A
- MNMD N/A
- Revenue Next Year
- TERN N/A
- MNMD N/A
- P/E Ratio
- TERN N/A
- MNMD N/A
- Revenue Growth
- TERN N/A
- MNMD N/A
- 52 Week Low
- TERN $1.87
- MNMD $4.70
- 52 Week High
- TERN $11.40
- MNMD $10.49
- Technical
- Relative Strength Index (RSI)
- TERN 71.76
- MNMD 57.66
- Support Level
- TERN $6.43
- MNMD $9.55
- Resistance Level
- TERN $6.34
- MNMD $10.49
- Average True Range (ATR)
- TERN 0.42
- MNMD 0.54
- MACD
- TERN 0.04
- MNMD -0.05
- Stochastic Oscillator
- TERN 98.68
- MNMD 68.77
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).